Last Updated: May 27, 2016
- Are TKIs favourable for the elderly with non-small-cell lung cancer?
Rossi Sabrina, et al. Oncotarget 2016 5 - 107P: A functional polymorphism located in intron of EGFR affects survival outcome of early-stage non-small cell lung cancer.
Hong M J, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S102-3 - 108P: Genetic polymorphisms in glycolytic pathway are associated with the prognosis of patients with early stage non-small cell lung cancer.
Choi J E, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S103 - 111P: Deltex-1 single nucleotide polymorphism rs1732786A>G is associated with the prognosis of surgically resected non-small cell lung cancer.
Lee J H, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S104 - 1310: Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomised controlled trial.
Han B, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S113-4 - 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6).
Schuler M, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S116-7 - 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs.
Liao B-C, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S123-4 - 149P: The role of CTCs and cfDNA for diagnosis and monitoring of EGFR mutations in advanced NSCLC patients.
Calabuig-Fariñas S, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S123 - 155P: PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Do S K, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S125 - 159P: Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations.
Coloma C Salvador, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S127 - 163P: Prevalence of epidermal growth factor receptor (EGFR) gene mutations in non small cell lung cancer (NSCLC) in Bulgarian population.
Popovska S, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S128-9 - 168P: Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study.
Cadranel J, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S130-1 - 167P: Efficacy of EGFR-TKIs for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Liu Y, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S130 - 166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series.
Pasello G, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S130 - 170P: Survival of lung adenocarcinoma patients with uncommon EGFR mutations in routine clinical practice in Slovenia.
Stanic K, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S131-2 - 580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience.
Normanno N, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S151 - 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC).
Jenkins S, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S153-4 - 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC.
Oxnard G R, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S154 - 8P EGFR, KRAS, BRAF, and PI3K mutations and ALK rearrangement in 327 consecutive Spanish non-squamous NSCLC patients.
Martorell P Martin, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S60 - 11P Prognostic impact of MET mutations in exon 14 and copy number alterations in a series of NSCLC patients.
Clavé S, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S61 - 56P Incidence of glutathione S-transferase M1 and T1 polymorphisms among the smoker populations of Tabuk.
Mir R, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S78 - 59PD Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis.
Han B, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S79-80 - 64P Identification of the functional significance of mutations using the novel Precision Cancer Analysis System.
Peled N, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 4 (4 Suppl) S82 - Update to Rociletinib Data with the RECIST Confirmed Response Rate.
Sequist Lecia V, et al. The New England journal of medicine 2016 5 - Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status.
Hsu Chia-Hung, et al. Oncotarget 2016 5 - Genetic variants in chromatin-remodeling pathway associated with lung cancer risk in a Chinese population.
Geng Liguo, et al. Gene 2016 5 - PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lee Shin Yup, et al. Scientific reports 2016 0 25952 - KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.
Gao Weimin, et al. Molecular carcinogenesis 2016 5 - Fine-mapping markers of lung cancer susceptibility in a sub-region of chromosome 19q13.3 among Chinese.
Yin Jiaoyang, et al. Oncotarget 2016 5 - Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival.
Maturu Venkata Nagarjuna, et al. Lung India : official organ of Indian Chest Society 0 0 (3) 257-66
- Human (3771)
- Pathogen (0)
- Human (56)
- Pathogen (0)
.png)
No hay comentarios:
Publicar un comentario